Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cns Pharmaceuticals Inc (NQ: CNSP )

0.1236 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Nov 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,030,527
Open 0.1236
Bid (Size) 0.1300 (107)
Ask (Size) 0.1308 (2)
Prev. Close 0.1236
Today's Range 0.1236 - 0.1236
52wk Range 0.0955 - 135.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting
Via Investor Brand Network
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
Via ACCESSWIRE

Performance

YTD
-99.79%
-99.79%
1 Month
-15.34%
-15.34%
3 Month
-25.54%
-25.54%
6 Month
-98.81%
-98.81%
1 Year
-99.88%
-99.88%

More News

Read More
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin Amid Strong Financial Position
Via Investor Brand Network
Exposures Product Safety
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
New Graphene Chip Could Revolutionize Brain Cancer Treatment
Via Investor Brand Network
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
Via ACCESSWIRE
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
Via ACCESSWIRE
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Berubicin’s Potential in Glioblastoma Treatment During KOL Connect Event
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Granted Nasdaq Extension for Compliance
Via Investor Brand Network
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Via ACCESSWIRE
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG
Via AB Newswire
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $3 Million in Registered Direct Offering
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Nasdaq Down 2%; US Crude Stocks Increase
Via Benzinga
Gold Moves Lower; AT&T Earnings Top Views
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Why CNS Pharmaceuticals (CNSP) Stock Is Up 86%
Via Benzinga
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Management, Dr. Samuel Goldlust Participate in Virtual Investor KOL Connect Segment
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.